Inogen (NASDAQ:INGN – Get Rating) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.
INGN has been the topic of a number of other research reports. Needham & Company LLC reiterated a “buy” rating and set a $26.00 price target on shares of Inogen in a report on Thursday, April 20th. William Blair cut shares of Inogen from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 17th.
Inogen Stock Performance
Inogen stock opened at $11.09 on Friday. Inogen has a 52 week low of $10.61 and a 52 week high of $32.01. The firm has a market capitalization of $256.40 million, a price-to-earnings ratio of -2.83 and a beta of 1.04. The company has a 50 day moving average price of $12.97 and a 200 day moving average price of $18.74.
Inogen (NASDAQ:INGN – Get Rating) last issued its earnings results on Thursday, May 4th. The medical technology company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.14. Inogen had a negative return on equity of 11.06% and a negative net margin of 24.36%. The business had revenue of $72.16 million during the quarter, compared to analysts’ expectations of $74.68 million. During the same quarter last year, the firm posted ($0.38) earnings per share. Inogen’s revenue was down 10.2% compared to the same quarter last year. Equities analysts forecast that Inogen will post -2.13 earnings per share for the current fiscal year.
Institutional Trading of Inogen
Hedge funds and other institutional investors have recently modified their holdings of the company. ExodusPoint Capital Management LP acquired a new position in Inogen in the first quarter worth approximately $1,758,000. Rhumbline Advisers boosted its holdings in Inogen by 5.1% in the first quarter. Rhumbline Advisers now owns 76,117 shares of the medical technology company’s stock worth $950,000 after purchasing an additional 3,682 shares in the last quarter. Credit Suisse AG boosted its holdings in Inogen by 23.5% in the first quarter. Credit Suisse AG now owns 27,600 shares of the medical technology company’s stock worth $344,000 after purchasing an additional 5,243 shares in the last quarter. Tocqueville Asset Management L.P. lifted its holdings in Inogen by 4.4% in the 1st quarter. Tocqueville Asset Management L.P. now owns 254,350 shares of the medical technology company’s stock worth $3,174,000 after purchasing an additional 10,650 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Inogen by 318.1% in the 1st quarter. Russell Investments Group Ltd. now owns 57,839 shares of the medical technology company’s stock worth $722,000 after purchasing an additional 44,005 shares during the last quarter. 95.93% of the stock is currently owned by hedge funds and other institutional investors.
Inogen Company Profile
Inogen, Inc is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home.